바이오인

The NIH Congressional Justification ("CJ") provides the Senate and House Appropriations Committees detailed estimates and justifications for research and research support activities (infrastructure, administrative, etc.) that NIH would anticipate funding at the President's Budget Request level.

The Overview section provides a narrative discussing NIH's past accomplishments in advancing the biomedical research enterprise, as well as current and future research endeavors of great promise. This section also provides NIH budget and employment summary tables (consolidated from those of all NIH's Institutes and Centers) and, justifications and tables for centrally provided services (the NIH Management Fund, and the NIH Service and Supply Fund)......more

OVERVIEW OF BUDGET REQUEST

For Fiscal Year (FY) 2016, NIH requests a total program level of $31.3 billion which is $1.0 billion above the FY 2015 Enacted level. This request reflects both the President’s and the Secretary’s commitment to improving the health of all Americans and to maintaining the country’s leadership in the biomedical sciences. For more than a hundred years, NIH has advanced the understanding of human health and disease through its investments in biomedical research, and the results of this research have helped improve health, lengthen life, and reduce illness and disability for many generations.

NIH’s work produces important secondary benefits to the Nation as well, including job creation, regional and global economic activity, international competitiveness, intellectual property, and commercializable products, to name a few. For example, a recent health and financial analysis of one clinical trial undertaken through NIH’s Women’s Health Initiative has demonstrated the robust return that NIH provides to the American public. The study estimated that one postmenopausal hormone therapy trial resulted in long-term financial and health outcomes worth $37.1 billion in net economic gain, a return of approximately $140 on every dollar invested in the trial.

In order to maintain excellence, NIH must continue to fund a strong, diverse portfolio of biomedical research, flexible enough to capitalize on scientific opportunities and to respond to urgent public health needs as they arise. For example, the recent Ebola epidemic in West Africa allowed NIH to demonstrate this flexibility in responding to a public health emergency. Numerous NIH-funded scientists utilized established biomedical research infrastructure to identify the source and track the spread of the epidemic using advanced genetic sequencing technologies, develop multiple promising vaccine candidates in tandem with the private sector, perform Phase I vaccine safety and efficacy clinical trials, and take steps to perform advanced clinical vaccine testing in an afflicted country.

To strike this delicate balance in its biomedical research portfolio, in FY 2016, NIH will on the following priority themes:

1. Unraveling Life’s Mysteries through Basic Research
2. Translating Discovery into Health
3. Harnessing Data and Technology to Improve Health
4. Preparing a Diverse and Talented Biomedical Research Workforce
By pursuing these priorities, NIH will continue to take on the critical scientific challenges that

By pursuing these priorities, NIH will continue to take on the critical scientific challenges that must be faced to improve health, reduce disability, and drive the engines of discovery and innovation. Often these challenges are ones that NIH is uniquely poised to pursue because of the Agency’s expertise, resources, and deep commitment to health and the public good.

...................(계속)

☞ 자세한 내용은 내용바로가기 또는 첨부파일을 이용하시기 바랍니다.